223 related articles for article (PubMed ID: 26061101)
1. Natural compound renews hope for diabetes and obesity therapeutic target.
Merk D; Schubert-Zsilavecz M
Future Med Chem; 2015; 7(7):833-5. PubMed ID: 26061101
[No Abstract] [Full Text] [Related]
2. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder.
Zhang S; Ma Y; Li J; Ma J; Yu B; Xie X
Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14571-6. PubMed ID: 25246581
[TBL] [Abstract][Full Text] [Related]
3. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Overton HA; Fyfe MC; Reynet C
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
[TBL] [Abstract][Full Text] [Related]
4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
Hodge RJ; Nunez DJ
Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of GPER in diabetes and atherosclerosis.
Barton M; Prossnitz ER
Trends Endocrinol Metab; 2015 Apr; 26(4):185-92. PubMed ID: 25767029
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids.
Kawser Hossain M; Abdal Dayem A; Han J; Yin Y; Kim K; Kumar Saha S; Yang GM; Choi HY; Cho SG
Int J Mol Sci; 2016 Apr; 17(4):569. PubMed ID: 27092490
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy for the patient with obesity.
Bray GA; Ryan DH
Circulation; 2012 Apr; 125(13):1695-703. PubMed ID: 22474312
[No Abstract] [Full Text] [Related]
9. Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies.
Sonnett TE; Levien TL; Gates BJ; Robinson JD; Campbell RK
Ann Pharmacother; 2010 Apr; 44(4):701-11. PubMed ID: 20233909
[TBL] [Abstract][Full Text] [Related]
10. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
Bryzgalova G; Effendic S; Khan A; Rehnmark S; Barbounis P; Boulet J; Dong G; Singh R; Shapses S; Malm J; Webb P; Baxter JD; Grover GJ
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):262-7. PubMed ID: 18621127
[TBL] [Abstract][Full Text] [Related]
11. Nomilin as an anti-obesity and anti-hyperglycemic agent.
Sato R
Vitam Horm; 2013; 91():425-39. PubMed ID: 23374727
[TBL] [Abstract][Full Text] [Related]
12. Compound and compositions as TGR5 agonists: WO2012082947.
Raval S
Expert Opin Ther Pat; 2013 Apr; 23(4):531-6. PubMed ID: 23409864
[TBL] [Abstract][Full Text] [Related]
13. Metabolic diseases.
Balfe A; Perry L
IDrugs; 2006 Nov; 9(11):754-5. PubMed ID: 17096291
[No Abstract] [Full Text] [Related]
14. Mushrooms of the Genus
Wińska K; Mączka W; Gabryelska K; Grabarczyk M
Molecules; 2019 Nov; 24(22):. PubMed ID: 31717970
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic phytogenic compounds for obesity and diabetes.
Jung HS; Lim Y; Kim EK
Int J Mol Sci; 2014 Nov; 15(11):21505-37. PubMed ID: 25421245
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and surgical treatments for obesity.
DeWald T; Khaodhiar L; Donahue MP; Blackburn G
Am Heart J; 2006 Mar; 151(3):604-24. PubMed ID: 16504622
[No Abstract] [Full Text] [Related]
17. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Harley EA; Levens N
Curr Opin Investig Drugs; 2003 Oct; 4(10):1179-89. PubMed ID: 14649209
[TBL] [Abstract][Full Text] [Related]
18. Natural Products Modulating Autophagy Pathway Against the Pathogenesis of Diabetes Mellitus.
Li L; Qi J; Li H
Curr Drug Targets; 2019; 20(1):96-110. PubMed ID: 30047328
[TBL] [Abstract][Full Text] [Related]
19. Regulation effects of TZQ-F on adipocyte differentiation and insulin action.
Nan Xia J; Qin Zhang D; Du J; Wen J
J Ethnopharmacol; 2013 Nov; 150(2):692-9. PubMed ID: 24095827
[TBL] [Abstract][Full Text] [Related]
20. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
Naruszewicz M
Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
